Journal Article10.1016/S0002-9149(97)00575-4
Design and Methodology of the PURSUIT Trial
79
TL;DR: The PURSUIT trial, the largest clinical trial of any GP IIb-IIIa receptor inhibitor to date, is a recently completed phase III evaluation of eptifibatide as primary management for patients with acute coronary syndromes presenting without persistent ST-segment elevation.
read more
Abstract: The acute ischemic coronary syndromes of unstable angina and non-Q-wave myocardial infarction are most commonly caused by intracoronary thrombosis at the site of ruptured atherosclerotic plaque. The main goals of therapy are the relief of ischemia and prevention of life-threatening thrombotic events. Current antithrombotic management includes heparin and aspirin, but recent insights into the pathophysiology of these syndromes have revealed that more effective management may be achieved by direct inhibition of the final common pathway to platelet aggregation--the platelet glycoprotein (GP) IIb-IIIa receptor. Earlier studies of the reversible peptide inhibitor of the GP IIb-IIIa receptor, eptifibatide (INTEGRILIN), in patients with unstable angina have demonstrated its potential in reducing acute ischemic events. The Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, the largest clinical trial of any GP IIb-IIIa receptor inhibitor to date, is a recently completed phase III evaluation of eptifibatide as primary management for patients with acute coronary syndromes presenting without persistent ST-segment elevation.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
TL;DR: The newly discovered roles for platelets as well as their role in hemostasis and thrombosis are covered and the promising receptor and enzymatic targets that may further decrease platelet activation are highlighted to address the myriad of pathologic conditions now known to involve platelets without significant effects on he mostasis.
174
The Development of Interventional Cardiology
TL;DR: Twenty years have passed since the beginning of clinical interventional cardiology on the occasion of the first angioplasty procedure performed by Andreas Gruentzig, and this discipline has evolved into a field ofiology.
66
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
K.M. Akkerhuis,Jaap W. Deckers,Eric Boersma,Robert A. Harrington,Janina Stępińska,Kenneth W. Mahaffey,Robert G. Wilcox,A.M. Lincoff,Matyas Keltai,Eric J. Topol,Robert M. Califf,Maarten L. Simoons +11 more
TL;DR: The analysis suggests that the apparent differences in patient outcome and eptifibatide treatment effect can be explained largely by differences in baseline demographics and adjunctive treatment strategies as well as by the methodology of myocardial infarction definition and the adjudication process.
64
Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
TL;DR: There exists a compelling rationale for long-term antiplatelet treatment, including parenteral treatment, for patients with the acute coronary syndromes and in maintaining patency of vascular grafts in the long term.
48
References
•Journal Article
Collaborative overview of randomized trials of antiplatelet therapy .1. prevention of death, myocardial-infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
R Altman,L Carreras,R Diaz,E Figueroa,E Paolasso,J C Parodi,J F Cade,G Donnan,M J Eadie,T P Gavaghan,E F Osullivan,D Parkin,Renny Jtg.,C Silagy,H Vinazzer,F Zekert,H Adriaensen,J M Bertrandhardy,M Bran,J L David,J Dricot,E Lavennepardonge,R Limet,A Lowenthal,M Moriau,S Schapira,P Smets,J Symoens,R Verhaeghe,Marc Verstraete,A Atallah,H Barnett,R Batista,J Blakely,J A Cairns,R Cote,J Crouch,G Evans,J M Findlay,M Gent,Y Langlois,J Leclerc,J Norris,G F Pineo,P J Powers,R Roberts,L Schwartz,J Sicurella,W Taylor,P Theroux,Alexander G.G. Turpie,R D Weisel,J Cui,L Liu,J Pirk,C Bay,G Boysen,J B Knudsen,P Petersen,P S Sorensen,H K Tonnesen,P T Harjola,J C Arcan,B Balkau,J Blanchard,J P Boissel,B Boneu,M G Bousser,M Brochier,M Cloarec,G Cribier,M Dechavanne,P Drouin,E Eschwege,B Guiraudchaumeil,R Hugonot,A Leizorovicz,Y Loria,L Michat,J Mirouze,E Panak,J Pasteyer,A Rascol,L Revol,Maarten Van Roy,J Selles,G Slama,C Starkman,M Teule,N Thibult,M Verry,F W Albert,K Andrassy,K Breddin,R Eckel,A Encke,J Frohlich,B Hartung,H W Heiss,H Hess,B Hofling,D Krause,G Latta,H Linke,D Loew,R Lorenz,K Middleton,G Novak,M Oldendorf,N Pfluger,D Raithel,R Reuter,G Schettler,J Schnitker,W Schoop,H Stiegler,K Uberla,G Vogel,M Weber,I Welbers,E Zeitler,G Arapakis,T Chan,C K Mok,R Szabo,N P Misra,K Reddy,G A Fitzgerald,A Apollonio,F Balsano,A Basellini,L Candelise,Mariella Catalano,N Ciavarella,G Ciuffetti,S Coccheri,M Cortellaro,G Corvi,V Coto,Giovanni Davì,R Decaterina,T Diperri,C Fieschi,R Gentile,L Gregoratti,Paolo Gresele,M Lavezzari,A Libretti,B Magnani,G.G. Nenci,G Pagano,Carlo Patrono,L Pedrini,M Pini,Paolo Prandoni,F Romeo,F Rovelli,G Rudelli,G Ruvolo,G P Signorini,G Tognoni,Francesco Violi,T Fujimori,M Kageyama,T Katsumura,S Kitamura,K Maeda,A Suzuki,H Tohgi,S Uchiyama,H Utsumi,A M Garcia,A Algra,Denottolander Gjh.,Kupper Ajf.,J Vangijn,H Hart,L J Kappelle,P J Koudstaal,T Lemmens,J Lodder,M Pannebakker,P W Serruys,A Vandenbelt,J Vandermeer,A B Vandervijgh,Verheugt Fwa.,G Veth,J Dale,K A Johannessen,E Thaulow,P Popescu,N Tiberiu,Aznar Jrd.,E Esmatjes,P Guiteras,J Lasierra,P Lopeztrigo,A Oriol,L Pomar,E Rocha,F D Sanchez,J Sanchorieger,G Sanz,Berglund Ulf.,C Blomstrand,M Boberg,M Britton,C E Elwin,C Helmers,J Holm,L Janzon,S Juulmoller,H Mulec,J E Olsson,S Persson,G Rasmanis,A Rosen,K Samuelsson,J Soreff,N Wahlgren,L Wallentin,H R Baur,M Bokslag,A Bollinger,B Meier,M Pfisterer,C Sitthiamorn,E J Acheson,P Appleby,A W Asscher,A Aukland,Colin Baigent,S Bala,A H Barnett,P Bell,S Bews,Born Gvr.,J P Branagan,N Brooks,M J Brown,N L Browse,R Capildeo,M Carmalt,A E Carter,I Chalmers,Mike Clarke,Robert Clarke,Clyne Cac.,Rory Collins,Cooke,G Coutts,D H Cove,P S Crowther,W F Cuthbertson,D Debono,C Dickerson,J P Dickinson,Richard Doll,J A Dormandy,D Dunbabin,S Ell,P Elphinstone,P Elwood,V Englishby,B Farrell,C Fiskerstrand,M Flather,T Foley,T Foulds,K M Fox,Peter Franks,H Fraser,T Gardecki,M Gawel,A E Gent,A H Gershlick,J Godwin,M Goldman,C Gray,D Gray,Richard Gray,H Handoll,G Hankey,Harrison Mjg.,N Henderson,S Heptinstall,S F Hobbiger,E W Jones,Jones Nag.,S Jost,D Julian,J Kellett,R C Kester,G Lowe,J Mackenzie,C N McCollum,G Mead,T W Meade,D Mendelow,J C Miller,G K Morris,C Nichol,M Noble,Obrien,M Ogier,Sarah Parish,M J Parry,Richard Peto,Janet T. Powell,P Pozzilli,N Qizilbash,A Rahman,S M Rajah,D H Richards,S Richards,Ruth M. Ripley,V C Roberts,F C Rose,Russell Rwr.,P C Rubin,C V Ruckley,Peter Sandercock,Shaw Mdm.,K M Shaw,J H Shelley,J Slattery,Peter Sleight,S J Smith,P Stewartlong,P M Sweetnam,Tansey Mjb.,H Tindall,J Turney,H M Tyler,N C Varey,M P Vessey,M G Walker,M A Walker,C P Warlow,R G Wilcox,H Willems,E H Wood,E Wynjones,H P Adams,B Barton,R F Bedford,B L Bick,S Bingham,B G Brown,T Bryant,J Buring,C F Cabot,P Canner,J Chesebro,O D Chrisman,G P Clagett,J A Colwell,M Dyken,D Ellis,W S Fields,C Furberg,V Fuster,S Goldman,J Granett,R M Green,D Green,R Hardy,L A Harker,W H Harris,R G Hart,W K Hass,Charles H. Hennekens,D Hill,M Hume,M C Igloe,G Johnson,S Jonas,G Knatterud,T R Kohler,N J Lembo,D Lewis,E Lockhart,P Majerus,Mcenany,R Mckenna,J L Mehta,J S Meyer,B Molony,T Moritz,D M Nicoloff,G Nycz,H Ono,G A Pantely,S J Phillips,Paul M. Ridker,J T Robertson,R Rothbart,E W Salzman,R D Sautter,R C Schlant,J A Schoenberger,M V Sengekontacket,G Sharma,P Steele,K P Steinnagel,J Stratton,J M Sullivan,G Timmis,J F Toole,Walker,S Weisman,C W White,M Wirecki,D Wombolt,R Wong,Salim Yusuf,K Zadina,D Zucker +418 more
TL;DR: There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.
3.8K
The pathogenesis of coronary artery disease and the acute coronary syndromes (1).
TL;DR: The two hypotheses to explain the pathogenesis of atherosclerosis, the "incrustation" hypothesis and the "lipid" hypothesis, are now known.
3.8K
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
TL;DR: Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.
2.6K
•Book
Hemostasis and thrombosis: Basic principles and clinical practice
Robert W. Colman
- 01 Jan 1982
TL;DR: Part I - BASIC PRINCIPLES of HEMOSTASIS and THROMBOSIS and CLINICAL APPLICATIONS.
2.1K